clinical trial · NCT04811040
Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
Gilead Sciences·phase1·completed·n = 32
HIV-1 InfectionOral LenacapavirSubcutaneous LenacapavirTeropavimabZinlirvimab
brief summary
The primary objective of this study is to evaluate the safety and tolerability of a combination of the broadly neutralizing antibodies (bNAbs) teropavimab (formerly GS-5423) and zinlirvimab (formerly GS-2872) in combination with the HIV capsid inhibitor lenacapavir (LEN).
started
Apr 8, 2021
primary completion
Jun 9, 2022
completion
Oct 26, 2023
last updated
Jan 27, 2025
official title
A Phase 1b Randomized, Blinded, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Broadly Neutralizing Antibodies (bNAbs) GS-5423 and GS-2872 in Combination With Capsid Inhibitor Lenacapavir (GS-6207) in Virologically Suppressed Adults With HIV-1 Infection
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol